Gene Therapy for Bietti's Eye Disease in Second Eye
Part of Eyes & vision clinical trials.
This study tests whether a gene therapy called VGR-R01 is safe when given to the second eye of people who already received it in their first eye as part of earlier trials. Bietti's crystalline dystrophy (BCD) is a genetic eye disease that causes vision loss over time, and this therapy aims to slow or stop that loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received VGR-R01 in one eye through a prior study (VGR-R01-001 or VGR-R01-101)
- Your second eye must have vision between hand motion and 75 ETDRS letters (a measure of how much you can see)
- You cannot have active eye infections or inflammation
- You cannot have other significant eye diseases like macular degeneration, diabetic eye disease, glaucoma, or retinal detachment
- You cannot have had eye surgery other than cataract surgery in the study eye
- You must be able to follow study instructions and provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers compassionate use of the gene therapy ZVS101e for people with Bietti crystalline dystrophy (BCD) who were in the control group of an earlier study. It aims to give extended treatment access to those who didn't receive the experimental therapy before.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests an investigational gene therapy called ZVS101e for people with Bietti's crystalline dystrophy (BCD), a rare inherited eye disease. It aims to see if the treatment can help slow vision loss or improve vision.
This Phase 1/2 study tests a gene therapy treatment (BS01) in people with retinitis pigmentosa to try to improve or preserve vision. You may be a candidate if your vision in at least one eye is quite limited and you haven’t had certain gene therapies before.
This trial tests a gene therapy called OPGx-BEST1 injected under the retina to treat vision loss from Best vitelliform macular dystrophy or a related condition. It may help people with advanced disease who have a specific genetic change in the BEST1 gene.
Hear when a new Bietti Crystalline Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.